Drug intelligence / Profile preview

HST 003

Development stage: Unknown
Lead developer: Histogen
Administration: Surgical Implant

Overview

**HST 003** is a human extracellular matrix (hECM) product developed by Histogen as a malleable scaffold for orthopedic tissue regeneration. It is implanted into microfracture interstices and cartilage defects during knee surgery to promote hyaline cartilage regeneration by stimulating the body's endogenous stem cells. Preclinical studies demonstrate its anti-inflammatory, angiogenic properties, and ability to induce mesenchymal stem cell proliferation while retaining stemness, leading to mature hyaline cartilage and vascularized bone formation in osteochondral lesion models.[1][2][3]

Other names: hECM:HST-003

Beyond the preview

Go deeper on HST 003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HST 003.

Explore the full profile